The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Collaboration in the industry needs to be institutionalised to drive the growth.
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
